Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases
Author:
Affiliation:
1. Department of Cardiology, Rinku General Medical Center
2. Department of Community Medicine, Osaka University Graduate School of Medicine
3. Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine
4. Sumitomo Hospital
Publisher
Japan Atherosclerosis Society
Subject
Biochemistry, medical,Cardiology and Cardiovascular Medicine,Internal Medicine
Link
https://www.jstage.jst.go.jp/article/jat/26/5/26_48918/_pdf
Reference76 articles.
1. 1) Oliver M: The clofibrate saga: a retrospective commentary. Br J Clin Pharmacol, 2012; 74: 907-910
2. 2) Issemann I and Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 1990; 347: 645-650
3. 3) Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E and Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 1998; 98: 2088-2093
4. 4) Fruchart JC, Duriez P and Staels B: Peroxisome proliferator-activated receptor-alpha activators regulate genes gov erning lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol, 1999; 10: 245-257
5. 5) Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T and Nikkilä EA: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med, 1987; 317: 1237-1245
Cited by 50 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Feasibility and efficacy of pemafibrate for prevention of maternal high-fat intake-induced glucose metabolic dysfunction in offspring;Biochemical Pharmacology;2024-09
2. Managing hypertriglyceridemia for cardiovascular disease prevention: Lessons from the PROMINENT trial;European Journal of Clinical Investigation;2024-04-25
3. Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review;Metabolism and Target Organ Damage;2024-04-07
4. Perspectives on the success of plasma lipidomics in cardiovascular drug discovery and future challenges;Expert Opinion on Drug Discovery;2023-12-12
5. Evaluation of the effects of pemafibrate on metabolic dysfunction‐associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis‐4 index and the magnetic resonance imaging‐aspartate aminotransferase score;JGH Open;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3